image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.9
1.06 %
$ 15.9 M
Market Cap
-0.04
P/E
1. INTRINSIC VALUE

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers.[ Read More ]

The intrinsic value of one OPGN stock under the base case scenario is HIDDEN Compared to the current market price of 1.9 USD, OpGen, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OPGN

image
FINANCIALS
3.42 M REVENUE
31.11%
-15.7 M OPERATING INCOME
54.61%
-32.7 M NET INCOME
12.38%
-14.3 M OPERATING CASH FLOW
29.98%
-800 K INVESTING CASH FLOW
-35.49%
8.37 M FINANCING CASH FLOW
224.31%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
8.83 M NET INCOME
660.35%
-2.83 M OPERATING CASH FLOW
-293.39%
0 INVESTING CASH FLOW
0.00%
4.3 M FINANCING CASH FLOW
592.34%
Balance Sheet Decomposition OpGen, Inc.
image
Current Assets 1.58 M
Cash & Short-Term Investments 1.15 M
Receivables 103 K
Other Current Assets 325 K
Non-Current Assets 302 K
Long-Term Investments 302 K
PP&E 138
Other Non-Current Assets 0
Current Liabilities 11.4 M
Accounts Payable 111 K
Short-Term Debt 11 M
Other Current Liabilities 289 K
Non-Current Liabilities 2.02 M
Long-Term Debt 2.02 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall OpGen, Inc.
image
Revenue 3.42 M
Cost Of Revenue 3.51 M
Gross Profit -90.7 K
Operating Expenses 30.7 M
Operating Income -15.7 M
Other Expenses 17 M
Net Income -32.7 M
RATIOS
-2.65% GROSS MARGIN
-2.65%
-458.95% OPERATING MARGIN
-458.95%
-955.69% NET MARGIN
-955.69%
282.56% ROE
282.56%
-1735.59% ROA
-1735.59%
2281.24% ROIC
2281.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OpGen, Inc.
image
Net Income -32.7 M
Depreciation & Amortization 1.32 M
Capital Expenditures -800 K
Stock-Based Compensation 236 K
Change in Working Capital -1.03 M
Others 16 M
Free Cash Flow -15.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OpGen, Inc.
image
OPGN has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership OpGen, Inc.
image
Sold
0-3 MONTHS
750 K USD 1
3-6 MONTHS
1.92 T USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
1.08 T USD 1
0-3 MONTHS
10.1 T USD 1
3-6 MONTHS
0 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 29, 2024
Bought 514 B USD
AEI Capital Ltd
10 percent owner
+ 514138
999998 USD
2 months ago
Aug 27, 2024
Bought 565 B USD
AEI Capital Ltd
10 percent owner
+ 564971
999999 USD
3 months ago
Aug 16, 2024
Bought 9.81 T USD
AEI Capital Ltd
10 percent owner
+ 3600000
2724490 USD
3 months ago
Aug 13, 2024
Bought 243 B USD
AEI Capital Ltd
10 percent owner
+ 566494
428724 USD
3 months ago
Aug 08, 2024
Sell 272 B USD
AEI Capital Ltd
10 percent owner
- 600000
454082 USD
3 months ago
Aug 05, 2024
Sell 1.64 T USD
AEI Capital Ltd
10 percent owner
- 1800000
913265 USD
2 months ago
Aug 23, 2024
Sell 750 K USD
AEI Capital Ltd
10 percent owner
- 263961
2.84 USD
3 months ago
Jul 30, 2024
Sell 0 USD
Lazar David E.
Chief Executive Officer
- 550000
0 USD
6 months ago
Apr 23, 2024
Bought 0 USD
Lazar David E.
Chief Executive Officer
+ 150000
0 USD
7 months ago
Apr 05, 2024
Bought 0 USD
Lazar David E.
Chief Executive Officer
+ 200000
0 USD
2 years ago
Jan 26, 2022
Bought 21.2 K USD
Bacher Johannes
Chief Operating Officer
+ 25000
0.85 USD
2 years ago
Nov 19, 2021
Bought 15.3 K USD
Bacher Johannes
Chief Operating Officer
+ 10000
1.5347 USD
3 years ago
Nov 18, 2021
Bought 15 K USD
Schacht Oliver
Chief Executive Officer
+ 10000
1.496 USD
3 years ago
Sep 15, 2021
Bought 15.4 K USD
Bacher Johannes
Chief Operating Officer
+ 5000
3.07 USD
3 years ago
Sep 15, 2021
Bought 15.4 K USD
Schacht Oliver
Chief Executive Officer
+ 5000
3.08 USD
3 years ago
Jun 10, 2021
Bought 1.62 K USD
Schacht Oliver
Chief Executive Officer
+ 720
2.25 USD
3 years ago
Jun 10, 2021
Bought 224 USD
Schacht Oliver
Chief Executive Officer
+ 100
2.245 USD
3 years ago
Jun 10, 2021
Bought 16.3 K USD
Schacht Oliver
Chief Executive Officer
+ 7280
2.24 USD
3 years ago
Jun 10, 2021
Bought 8.47 K USD
Schacht Oliver
Chief Executive Officer
+ 3800
2.23 USD
3 years ago
Jun 10, 2021
Bought 11.2 K USD
Schacht Oliver
Chief Executive Officer
+ 5000
2.237 USD
3 years ago
Jun 10, 2021
Bought 3.78 K USD
Schacht Oliver
Chief Executive Officer
+ 1700
2.225 USD
3 years ago
Jun 10, 2021
Bought 3.11 K USD
Schacht Oliver
Chief Executive Officer
+ 1400
2.22 USD
3 years ago
Jun 10, 2021
Bought 21.6 K USD
Bacher Johannes
Chief Operating Officer
+ 9394
2.3 USD
3 years ago
Jun 10, 2021
Bought 1.39 K USD
Bacher Johannes
Chief Operating Officer
+ 606
2.29 USD
3 years ago
Jun 10, 2021
Bought 22.5 K USD
Bacher Johannes
Chief Operating Officer
+ 10000
2.25 USD
4 years ago
Oct 27, 2020
Sell 4.11 K USD
JONES EVAN/ FA
Director
- 1748
2.35 USD
4 years ago
Sep 04, 2020
Sell 7.91 K USD
JONES EVAN/ FA
Director
- 3612
2.19 USD
4 years ago
May 07, 2020
Sell 41.8 USD
Curetis N.V. in Liquidation
10 percent owner
- 19
2.2 USD
4 years ago
Apr 22, 2020
Sell 94.9 K USD
Curetis N.V. in Liquidation
10 percent owner
- 42375
2.24 USD
4 years ago
Apr 23, 2020
Sell 101 K USD
Curetis N.V. in Liquidation
10 percent owner
- 46612
2.17 USD
4 years ago
Apr 17, 2020
Sell 408 K USD
Curetis N.V. in Liquidation
10 percent owner
- 165902
2.46 USD
4 years ago
Apr 20, 2020
Sell 130 K USD
Curetis N.V. in Liquidation
10 percent owner
- 55142
2.35 USD
4 years ago
Apr 21, 2020
Sell 220 K USD
Curetis N.V. in Liquidation
10 percent owner
- 95609
2.3 USD
5 years ago
Nov 11, 2019
Sell 7.74 K USD
JONES EVAN/ FA
Chief Executive Officer
- 6000
1.29 USD
5 years ago
Mar 28, 2019
Bought 250 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 417000
0.6 USD
7 years ago
Jul 05, 2017
Bought 110 K USD
jVen Capital, LLC
Chairman and CEO
+ 158730
0.69 USD
7 years ago
Jun 28, 2017
Bought 110 K USD
jVen Capital, LLC
Chairman and CEO
+ 140845
0.78 USD
7 years ago
Jul 18, 2017
Bought 750 K USD
jVen Capital, LLC
Chairman and CEO
+ 1875000
0.4 USD
7 years ago
Jul 18, 2017
Bought 797 K USD
jVen Capital, LLC
Chairman and CEO
+ 1875000
0.425 USD
7 years ago
Jul 18, 2017
Bought 26 K USD
DEC TIMOTHY C
Chief Financial Officer
+ 65000
0.4 USD
7 years ago
Jul 05, 2017
Bought 124 K USD
jVen Capital, LLC
Chairman and CEO
+ 158730
0.78 USD
7 years ago
Jun 28, 2017
Bought 117 K USD
jVen Capital, LLC
Chairman and CEO
+ 149788
0.78 USD
7 years ago
Jun 28, 2017
Bought 54.9 K USD
jVen Capital, LLC
Chairman and CEO
+ 70423
0.78 USD
8 years ago
Jun 27, 2016
Bought 2.69 M USD
Merck & Co., Inc.
10 percent owner
+ 2050821
1.3125 USD
8 years ago
May 19, 2016
Bought 3.13 M USD
Merck & Co., Inc.
10 percent owner
+ 2734427
1.1438 USD
8 years ago
May 19, 2016
Bought 1.18 M USD
Merck & Co., Inc.
10 percent owner
+ 900000
1.3125 USD
8 years ago
May 19, 2016
Bought 437 USD
KRENITSKY KEVIN
President
+ 43716
0.01 USD
8 years ago
May 19, 2016
Bought 57.4 K USD
KRENITSKY KEVIN
President
+ 43716
1.3125 USD
8 years ago
May 19, 2016
Bought 8.74 K USD
jVen Capital, LLC
10 percent owner
+ 874317
0.01 USD
8 years ago
May 19, 2016
Bought 1.15 M USD
jVen Capital, LLC
10 percent owner
+ 874317
1.3125 USD
8 years ago
May 19, 2016
Bought 8.74 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 874317
0.01 USD
8 years ago
May 19, 2016
Bought 1.15 M USD
JONES EVAN/ FA
Chief Executive Officer
+ 874317
1.3125 USD
8 years ago
May 19, 2016
Bought 437 USD
Harris Timothy J.R.
Director
+ 43716
0.01 USD
8 years ago
May 19, 2016
Bought 57.4 K USD
Harris Timothy J.R.
Director
+ 43716
1.3125 USD
8 years ago
May 19, 2016
Bought 437 USD
DEC TIMOTHY C
Chief Financial Officer
+ 43716
0.01 USD
8 years ago
May 19, 2016
Bought 57.4 K USD
DEC TIMOTHY C
Chief Financial Officer
+ 43716
1.3125 USD
8 years ago
Dec 11, 2015
Bought 1.97 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 1105
1.7827 USD
8 years ago
Dec 10, 2015
Bought 183 USD
JONES EVAN/ FA
Chief Executive Officer
+ 100
1.83 USD
8 years ago
Dec 10, 2015
Bought 82.5 USD
JONES EVAN/ FA
Chief Executive Officer
+ 50
1.65 USD
8 years ago
Dec 07, 2015
Bought 1.07 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 600
1.7883 USD
8 years ago
Dec 04, 2015
Bought 527 USD
JONES EVAN/ FA
Chief Executive Officer
+ 300
1.7566 USD
9 years ago
May 08, 2015
Bought 2.47 M USD
Versant Ventures III, LLC
10 percent owner
+ 410906
6 USD
9 years ago
May 08, 2015
Bought 2.71 M USD
Versant Ventures III, LLC
10 percent owner
+ 410906
6.6 USD
9 years ago
May 08, 2015
Bought 14.6 K USD
Versant Ventures III, LLC
10 percent owner
+ 2426
6 USD
9 years ago
May 08, 2015
Bought 16 K USD
Versant Ventures III, LLC
10 percent owner
+ 2426
6.6 USD
9 years ago
May 08, 2015
Bought 1.8 M USD
Ushio Misti
Director
+ 300833
6 USD
9 years ago
May 08, 2015
Bought 1.99 M USD
Ushio Misti
Director
+ 300833
6.6 USD
9 years ago
May 08, 2015
Bought 50 K USD
KRENITSKY KEVIN
President
+ 8334
6 USD
9 years ago
May 08, 2015
Bought 55 K USD
KRENITSKY KEVIN
President
+ 8334
6.6 USD
9 years ago
May 08, 2015
Bought 2.94 M USD
jVen Capital, LLC
10 percent owner
+ 445000
6.6 USD
9 years ago
May 08, 2015
Bought 2.67 M USD
jVen Capital, LLC
10 percent owner
+ 445000
6 USD
9 years ago
May 08, 2015
Bought 2.67 M USD
JONES EVAN/ FA
Chief Executive Officer
+ 445000
6 USD
9 years ago
May 08, 2015
Bought 2.94 M USD
JONES EVAN/ FA
Chief Executive Officer
+ 445000
6.6 USD
9 years ago
May 08, 2015
Bought 55 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 8333
6.6 USD
9 years ago
May 08, 2015
Bought 50 K USD
JONES EVAN/ FA
Chief Executive Officer
+ 8333
6 USD
9 years ago
May 08, 2015
Bought 75 K USD
Howe Timothy
Director
+ 12500
6 USD
9 years ago
May 08, 2015
Bought 82.5 K USD
Howe Timothy
Director
+ 12500
6.6 USD
9 years ago
May 08, 2015
Bought 42.2 K USD
Harris Timothy J.R.
Director
+ 6400
6.6 USD
9 years ago
May 08, 2015
Bought 38.4 K USD
Harris Timothy J.R.
Director
+ 6400
6 USD
9 years ago
May 08, 2015
Bought 1.8 M USD
HARRIS & HARRIS GROUP INC /NY/
10 percent owner
+ 300833
6 USD
9 years ago
May 08, 2015
Bought 1.99 M USD
HARRIS & HARRIS GROUP INC /NY/
10 percent owner
+ 300833
6.6 USD
9 years ago
May 08, 2015
Bought 26.4 K USD
DEC TIMOTHY C
Chief Financial Officer
+ 4000
6.6 USD
9 years ago
May 08, 2015
Bought 24 K USD
DEC TIMOTHY C
Chief Financial Officer
+ 4000
6 USD
9 years ago
May 08, 2015
Bought 2.48 M USD
ATWOOD BRIAN G
director, 10 percent owner:
+ 413332
6 USD
9 years ago
May 08, 2015
Bought 2.73 M USD
ATWOOD BRIAN G
director, 10 percent owner:
+ 413332
6.6 USD
7. News
OPGN Stock Earnings: OpGen Reported Results for Q2 2024 OpGen (NASDAQ: OPGN ) just reported results for the second quarter of 2024. OpGen reported earnings per share of -$1.18. investorplace.com - 2 months ago
OPGN Stock Earnings: OpGen Meets Revenue for Q4 2023 OpGen (NASDAQ: OPGN ) just reported results for the fourth quarter of 2023. OpGen reported earnings per share of -$17.67. investorplace.com - 5 months ago
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). globenewswire.com - 5 months ago
OpGen Announced 1-for-10 Reverse Stock Split ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol “OPGN.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. globenewswire.com - 6 months ago
OpGen Provides Update on Business Operations and Strategic Opportunities ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's (“Curetis”), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. globenewswire.com - 6 months ago
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC disclosing that it was unable to file the Form 10-K by April 1, 2024 without unreasonable effort or expense. globenewswire.com - 6 months ago
OpGen Announces Acquisition of Preferred Stock by David Lazar ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million. The proceeds of the transaction will be used to repay and settle outstanding indebtedness and liabilities of the Company and for other general corporate and operating purposes. globenewswire.com - 7 months ago
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results. globenewswire.com - 1 year ago
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses. globenewswire.com - 1 year ago
Why Is OpGen (OPGN) Stock Up 540% Today? OpGen (NASDAQ: OPGN ) stock is undergoing a massive rally on Thursday following a couple of pieces of news from the precision medicine company. The first bit of news worth mentioning is a progress update on a product sale. investorplace.com - 1 year ago
Why Is OpGen (OPGN) Stock Up 115% Today? OpGen (NASDAQ: OPGN ) stock is on the rise Friday after the precision medicine company withdrew a share offering. A filing with the Securities and Exchange Commission (SEC) has the company requesting the withdrawal of its Registration Statement on Form S-1. investorplace.com - 1 year ago
OpGen, Inc. (OPGN) Q2 2023 Earnings Call Transcript OpGen, Inc. (NASDAQ:OPGN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - Chief Financial Officer Conference Call Participants Operator Welcome to OpGen's Second Quarter 2023 Earnings Call and Business Update. Before we turn the call over to OpGen management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. seekingalpha.com - 1 year ago
8. Profile Summary

OpGen, Inc. OPGN

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 15.9 M
Dividend Yield 0.00%
Description OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Contact 9717 Key West Avenue, Rockville, MD, 20850 https://www.opgen.com
IPO Date May 5, 2015
Employees 85
Officers Mr. Honjian Tan Chief Executive Officer & Chairman Dr. Oliver Schacht Ph.D. Executive Vice President of Corporate Development